HeyJaredAI For Pharma Growth
AI For Pharma Growth is the podcast from pioneering Artificial Intelligence entrepreneur Dr. Andree Bates created to help Pharma, Biotech and other Healthcare companies understand how the use of AI-based technologies can easily save them time and grow their brands and company…
- Indexed episodes, last 90 days
- 11
- Latest publication
- Sep 15, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 7, 2026
Latest episodes
E235: AI created a trust crisis and nobody is talking about it (opens the original)
Read excerpt
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dan Pratl, founder and CEO of Quadron Inc, about a trust problem emerging as AI moves deeper into pharma: how do organisations preserve confidence when more work is generated, shaped and accelerated by machines? Dan argues that verified output alone is not enough. Pharma already has human review, MLR, regulatory sign-off and quality controls, but trust also depends on understanding where data came from, which models were used,
E234: The contrarian case for physics over data: can deterministic, training-free models beat ML in lead optimization? (opens the original)
Read excerpt
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Jacek Marczyk, co-founder and CEO of BioDynLab, about a contrarian view of computational drug discovery: that the next leap may come not from more data and bigger models, but from physics. Dr. Marczyk brings a background in aerospace engineering, automotive, Silicon Graphics and complexity science. His work led to quantitative complexity theory, which he now applies to molecules through BioDynLab’s deterministic, training-f
E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named (opens the original)
Read excerpt
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores the AI capability problem pharma has not properly named: training that works in the room, but fails to hold inside the organisation. Dr Andree explains why one-off workshops, generic AI fluency programmes and broad learning platforms are not enough. They may teach people what AI is, what it can do and where it can fail, but they rarely teach the exact workflows, judgement calls and regulatory context people need for their own
E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner (opens the original)
Read excerpt
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Tom Coates, CEO of Presentient, about why interim analysis in clinical trials is ready for a major upgrade. Interim analyses allow sponsors to look at trial data mid-flight and assess whether a study is likely to succeed or fail, using pre-specified rules. But Tom explains that many phase two and three commercial trials still do not include a pre-planned interim analysis, meaning sponsors often wait far longer than necessary to
E231: The Diagnostic Room: You didn't have an AI problem. You had a capability problem. (opens the original)
Read excerpt
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores why many pharma teams do not have an AI problem at all. They have a capability problem. Dr Andree starts with a simple question: when was your team last properly trained on AI for their specific role? Not when they were given access to tools, licences or a generic use policy, but when they were trained to use AI effectively, safely and compliantly in their actual workflow. The episode challenges the usual explanations for dis
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.